Hematologic oncology trial representation in FIH cohort quantified
Source type:
obs· Harvested: 2026-05-04 · Original date: 2026-05-04T04:33:52.444Z Metadata:{"project":"oncology-fih-research/oncology-fih-research","type":"discovery","obs_id":65387}
obs/65387 · discovery · 2026-05-04T04:33:52.444Z
Hematologic oncology trial representation in FIH cohort quantified
Quantitative text analysis of ctgov_jho_trials_latest.csv dataset confirms significant hematologic oncology representation within the early-phase FIH-enriched landscape. Using regex pattern matching across trial titles, conditions, interventions, and sponsors, the analysis identified 1588 trials (16.4%) mentioning lymphoma, myeloma, leukemia, or related hematologic malignancies. CAR-T therapy signals appeared across multiple spelling variants totaling 178 unique mentions. Target-specific counts showed CD19 (51 trials) and BCMA (21 trials) as prominent. Named bispecific antibodies from the B-cell maturation antigen and CD20×CD3 classes were detected at lower frequencies, consistent with more recent emergence of these modalities. The overlap analysis revealed 84 hematologic trials tagged as bispecific and 92 as cell therapy, indicating substantial modality convergence in hematologic malignancies. These findings support the manuscript narrative that early-phase oncology infrastructure serves both solid tumor and hematologic disease development, with specialized toxicity management and referral networks required for cellular therapies and bispecific immune engagers.
Concepts: [“what-changed”,“how-it-works”,“problem-solution”]
Facts: [“Phase 1-like cohort contains 1588 trials with hematologic condition keywords (16.4% of 9659 trials)”,“CAR-T mentions appear in 86 trials using “car-t” spelling, 45 using “car t”, and 47 using “cart"",“BCMA-targeting trials number 21, CD19-targeting trials number 51”,“Specific bispecific antibodies identified: teclistamab (4), talquetamab (3), elranatamab (1), glofitamab (3), epcoritamab (3), mosunetuzumab (1), linvoseltamab (4)”,“Hematologic trials overlap with 84 bispecific antibody trials and 92 cell therapy trials”]
[← 回 Alfred Brain Hub]